Photo by paipai90 from unsplash
Recombinant human lymphotoxin‐α derivative (rhLTα‐Da) is a lymphotoxin‐α derivative that is missing 27 N‐terminal amino acid residues. Previous studies indicated a benefit from the addition of rhLTα‐Da to cisplatin‐based treatment… Click to show full abstract
Recombinant human lymphotoxin‐α derivative (rhLTα‐Da) is a lymphotoxin‐α derivative that is missing 27 N‐terminal amino acid residues. Previous studies indicated a benefit from the addition of rhLTα‐Da to cisplatin‐based treatment in patients with metastatic esophageal squamous cell carcinoma. The current study was conducted to evaluate the efficacy and safety of rhLTα‐Da plus cisplatin and fluorouracil (PF) in patients with mESCC.
Keywords:
recombinant human;
lymphotoxin;
metastatic esophageal;
patients metastatic;
lymphotoxin derivative;
human lymphotoxin
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!